Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 13/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795980 | 0.90 | TACR1 (0.41) | ROCK2ROCK1TACR1TNIKSIRT2 | |
| SCHEMBL6799968 | 0.90 | ROCK2 (0.40) | ROCK2ROCK1TACR1TNIKADRB2 | |
| SCHEMBL6794050 | 0.89 | ROCK2 (0.44) | ROCK2ROCK1TACR1TNIKADRB2 | |
| SCHEMBL6789592 | 0.89 | ROCK2 (0.42) | ROCK2ROCK1TACR1TNIKADRB2 | |
| SCHEMBL6794717 | 0.89 | ROCK2 (0.42) | ROCK2ROCK1TACR1TNIKADRB2 | |
| SCHEMBL6793859 | 0.88 | ROCK2 (0.43) | ROCK2ROCK1TACR1TNIKADRB2 | |
| SCHEMBL6795924 | 0.88 | ROCK2 (0.43) | ROCK2ROCK1TACR1TNIKADRB2 | |
| SCHEMBL6795052 | 0.88 | ROCK2 (0.42) | ROCK2ROCK1TACR1TNIKADRB2 | |
| SCHEMBL6790363 | 0.88 | ROCK2 (0.42) | ROCK2ROCK1TACR1TNIKADRB2 | |
| SCHEMBL6795197 | 0.88 | ROCK2 (0.42) | ROCK2ROCK1TACR1TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6147071-A | TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-14 | — | — | US | claimed |
| US-20040058914-A1 | Combination drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040023843-A1 | Preventives/remedies for emotional disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1352659-A1 | COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1323429-A1 | PREVENTIVES/REMEDIES FOR EMOTIONAL DISORDERS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-0733632-B1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6489315-B1 | NOVEL CYCLIC COMPOUNDS HAVING AN EXCELLENT TACHYKININ RECEPTOR ANTAGONISTIC EFFECT, AND A METHOD FOR PRODUCING THEM, FOR TREATING DISORDERS OF INCONTINENCE, ASTHMA, MIGRAINE, IRRITABLE BOWEL SYNDROME, PAIN, COUGH OR EMESIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020132817-A1 | Heterocyclic compounds, their production and use | NATSUGARI HIDEAKI (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1184036-A2 | Heterocyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
| EP-1145714-A1 | DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2001-10-17 | — | — | EP | disclosed |
| CN-1291099-A | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-11 | — | — | CN | disclosed |
| US-6147071-A | TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0733632-A1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023843-A1 | Preventives/remedies for emotional disorders | MTNR1A, KISS1R, MTNR1B | ROCK2 4150/4885ROCK1 2786/4885TACR1 12/4885 |
| US-20020132817-A1 | Heterocyclic compounds, their production and use | CRH, CRHR1, CRHR2 | ROCK2 1761/4885ROCK1 1349/4885TACR1 97/4885 |
| US-20040058914-A1 | Combination drugs | CHRNA1, CHRNA2, CHRM2 | ROCK2 753/4885ROCK1 985/4885TACR1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.